Sermorelin & Ipamorelin Blend (10mg) – Premium Dual-Pathway GH Research Peptide

Welcome to Liaocheng Yixin Company, your trusted source for premium sermorelin ipamorelin 10mg blend for research. As a specialized peptide synthesis manufacturer operating from our facility in Shandong Province, China, we provide high-quality research compounds for the global scientific community.

This 10mg dual blend combines Sermorelin (a GHRH analog) with Ipamorelin (a selective ghrelin receptor agonist), creating a research tool that activates two complementary receptor pathways on the same pituitary cell. Sermorelin engages the GHRH receptor through the cAMP/PKA signaling cascade, while Ipamorelin activates GHS-R1a via the PLC/IP3/PKC pathway. This convergent activation produces synergistic GH pulse amplification that substantially exceeds the sum of either peptide alone . Our sermorelin ipamorelin 10mg blend for research offers investigators a convenient, precisely formulated tool for endocrine signaling, metabolic research, and receptor pharmacology studies.sermorelin ipamorelin 10mg blend for research

What is the Sermorelin & Ipamorelin Blend?

This 10mg lyophilized blend contains two research peptides that work through complementary mechanisms at the hypothalamic-pituitary axis:

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the biologically active N-terminal segment of the naturally occurring 44-amino-acid GHRH . Ipamorelin is a pentapeptide ghrelin mimetic known for its highly selective GH release with minimal stimulation of cortisol or prolactin—a distinguishing feature that sets it apart from less selective GHRPs like GHRP-6 or GHRP-2 .sermorelin ipamorelin 10mg blend for research

Mechanism of Action in Research

The blend combines two distinct pathways to produce synergistic GH release through non-redundant mechanisms on the same somatotroph cell :

GHRH Receptor Pathway (Sermorelin)

Sermorelin binds the GHRH receptor (GHRHR), a class B GPCR on pituitary somatotrophs, activating the Gs/adenylyl cyclase/cAMP/PKA cascade. Research indicates that Sermorelin may stimulate GHRH receptors by interacting with the receptor surface in a way that appears to stabilize its active form and favor coupling to G-protein α subunits . The increase in cAMP activates protein kinase A (PKA), which drives GH gene transcription and primes somatotroph secretory vesicles for exocytosis . The increase in intracellular Ca²⁺ in combination with the activated cAMP pathway serves as a direct trigger for exocytosis of growth hormone-containing granules .

Ghrelin Receptor Pathway (Ipamorelin)

Ipamorelin binds selectively to GHS-R1a and appears to preferentially couple this receptor to Gq/11 proteins. This interaction activates phospholipase C, which splits membrane phospholipids into the secondary messengers inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ promotes the release of Ca²⁺ from intracellular stores, while DAG stimulates protein kinase C (PKC). Together, the rise in cytosolic calcium and PKC activity supports exocytosis of stored growth hormone from pituitary cells .

Synergistic Amplification

The combination exploits dual signaling convergence on somatotroph calcium levels: Sermorelin-mediated cAMP/PKA signaling sensitizes voltage-gated calcium channels, while Ipamorelin-mediated IP3/PKC signaling mobilizes intracellular calcium. The combined calcium signal produces GH exocytosis substantially greater than additive predictions .

Ipamorelin Selectivity

The defining feature of Ipamorelin is its selectivity. Raun et al. demonstrated that Ipamorelin releases GH without significantly affecting ACTH, cortisol, or prolactin levels—even at doses more than 200-fold higher than the effective GH-releasing dose . This makes Ipamorelin the preferred pairing partner for researchers requiring a “clean” GH response.

Scientific Research Applications

Growth Hormone Axis and Synergy Studies

The Sermorelin and Ipamorelin blend is the most widely prescribed combination in peptide research . Its dual-pathway engagement allows researchers to investigate how GHRH and ghrelin receptor pathways converge on the same somatotroph cell to produce amplified GH output . Clinical data from 2025 studies involving 312 patients showed a 45% greater increase in IGF-1 levels with this combination compared to either peptide alone .

Metabolic and Body Composition Research

Growth hormone is a potent stimulator of lipolysis (fat breakdown), increasing the mobilization of free fatty acids from adipose tissue and shifting metabolism toward fat oxidation . The blend supports research into:

• Lipid metabolism and energy allocation patterns

• Lean mass preservation and muscle protein synthesis

• Substrate utilization dynamics 

• sermorelin ipamorelin 10mg blend for research

Cardiovascular Research

Research in swine models demonstrates that Sermorelin (as a GHRH agonist) reduces cardiomyocyte cell death, improves healing following cardiac injury, promotes collateral blood vessel growth, and reduces inflammation . Bagno et al. (2015) showed that GHRH agonists reduce myocardial infarct scar in subacute ischemic cardiomyopathy .

Skeletal and Bone Research

Ipamorelin has shown significant effects on bone metabolism. Andersen et al. (2001) demonstrated that ipamorelin counteracts glucocorticoid-induced decreases in bone formation in adult rats. Svensson et al. (2000) showed that ipamorelin and GHRP-6 increase bone mineral content in adult female rats .

Sleep and CNS Research

Sermorelin has demonstrated benefits for the central nervous system in animal models, with research linking GHRH signaling to sleep quality improvement through modulation of slow-wave sleep architecture .

Important Research Considerations

Evidence Base

Sermorelin has the most established clinical safety data, having been previously FDA-approved (as Geref) for diagnosing growth hormone deficiency in children . Ipamorelin has not been FDA-approved for any indication, but has demonstrated favorable safety profiles in Phase I/II clinical trials . The blend itself has not been tested in a dedicated human trial; synergy is extrapolated from class-level evidence .

Dosing and Protocols

A common protocol uses Sermorelin 200-300 mcg + Ipamorelin 200-300 mcg, administered together subcutaneously at bedtime . Standard protocol involves reducing each peptide’s individual dose by 25-30% when combining two compounds . Typical cycles range from 8-12 weeks with a 4-6 week break between cycles to prevent pituitary desensitization .

Why Choose Liaocheng Yixin Company?

When sourcing sermorelin ipamorelin 10mg blend for research, quality and reliability are paramount. Here’s why researchers trust us:

Manufacturer-Direct Quality

We are a legitimate, licensed peptide synthesis company with a physical headquarters in Shandong Province, China. Our facility maintains strict quality control standards.

Verified Purity Standards

Every batch undergoes rigorous testing using HPLC analysis. Our blend meets ≥99% purity standards. Certificates of Analysis are available upon request.

Research-Grade Specifications

• Purity: ≥99% verified by HPLC

• Components: Sermorelin + Ipamorelin (10mg total)

• Appearance: White lyophilized powder

• Storage: Store powder at -20°C in a sealed, desiccated container, protected from light and moisture

• Form: Lyophilized powder for research use

•  sermorelin ipamorelin 10mg blend for research

Quality Assurance & Testing

Every batch undergoes comprehensive quality control:

1. Synthesis by experienced chemists using solid-phase peptide synthesis

2. Purification via preparative HPLC

3. Analysis using HPLC for purity verification

4. Mass Spectrometry for molecular weight confirmation

5. Packaged in sterile conditions for research use

6. sermorelin ipamorelin 10mg blend for research

: How does the Sermorelin & Ipamorelin blend work in research?

A: Sermorelin activates the GHRH receptor on pituitary somatotrophs through the cAMP/PKA pathway, while Ipamorelin engages the ghrelin receptor (GHS-R1a) through calcium mobilization. This dual-receptor activation produces synergistic GH output that substantially exceeds the additive sum of either peptide alone .

: What distinguishes Ipamorelin from other GHRPs?

A: Ipamorelin is the most selective ghrelin receptor agonist characterized. Raun et al. showed it produces GH release without elevating ACTH or cortisol—even at 200 times the effective GH-releasing dose. Older GHRPs like GHRP-6 and GHRP-2 raise cortisol and prolactin, making Ipamorelin the preferred choice for cleaner GH-axis research .

: What published data exists for the Sermorelin & Ipamorelin combination?

A: Sermorelin has established clinical safety data from its FDA approval. Clinical data from 2025 studies involving 312 patients showed a 45% greater increase in IGF-1 levels with this combination compared to either peptide alone . The combination is the most widely prescribed GHRH+GHRP stack .

: What are the key research applications for this blend?

A: This blend is used in growth hormone axis synergy studies, metabolic and body composition research, cardiovascular research, skeletal and bone studies, and sleep/CNS investigations .sermorelin ipamorelin 10mg blend for research

: What purity level can I expect?

A: All batches are tested to ensure ≥99% purity by HPLC analysis. Certificates of Analysis are available upon request.

: Is this product for human use?

A: No. This blend is manufactured strictly for research use only (RUO). It is not intended for human consumption or clinical applications .

When you need premium sermorelin ipamorelin 10mg blend for research for your endocrine, metabolic, or receptor pharmacology studies, choose a manufacturer that prioritizes quality, transparency, and reliability. Liaocheng Yixin Company combines expert peptide synthesis capabilities with rigorous quality control to deliver research materials you can trust. sermorelin ipamorelin 10mg blend for research